Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment, prospectively or retrospectively, to this sub-study per inclusion and exclusion criteria.
Symptomatic drug refractory paroxysmal (AF episode terminate spontaneously within 7 days) who, in the opinion of the investigator, are candidates for ablation for AF
18 years of age or older
Able and willing to participate in baseline and follow up evaluations for the full length of the sub-study
Willing and able to provide informed consent for this sub-study
Patients who have undergone catheter ablation for atrial fibrillation (PVI, roof line, posterior wall ablation...)
Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan
Persistent or long-standing persistent AF
In the opinion of the investigator, any known contraindication to an ablation procedure
Heart Rhythm Clinical and Research Solutions, LLC
Lead sponsor
Biosense Webster, Inc.
Collaborator